We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Read MoreHide Full Article
Merck (MRK - Free Report) closed the most recent trading day at $150.32, moving -1.33% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.38% for the day. At the same time, the Dow lost 0.51%, and the tech-heavy Nasdaq lost 0.29%.
Heading into today, shares of the pharmaceutical company had gained 18.67% over the past month, outpacing the Medical sector's gain of 6.34% and the S&P 500's gain of 2.08%.
The upcoming earnings release of Merck will be of great interest to investors. On that day, Merck is projected to report earnings of $2.27 per share, which would represent a year-over-year decline of 12.02%. In the meantime, our current consensus estimate forecasts the revenue to be $17.61 billion, indicating a 1.94% growth compared to the corresponding quarter of the prior year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $2.97 per share and a revenue of $67.25 billion, signifying shifts of -66.93% and +3.45%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Merck. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.33% lower. As of now, Merck holds a Zacks Rank of #3 (Hold).
In terms of valuation, Merck is presently being traded at a Forward P/E ratio of 51.22. For comparison, its industry has an average Forward P/E of 18.02, which means Merck is trading at a premium to the group.
We can additionally observe that MRK currently boasts a PEG ratio of 6.16. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.3 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 98, finds itself in the top 40% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Merck (MRK - Free Report) closed the most recent trading day at $150.32, moving -1.33% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.38% for the day. At the same time, the Dow lost 0.51%, and the tech-heavy Nasdaq lost 0.29%.
Heading into today, shares of the pharmaceutical company had gained 18.67% over the past month, outpacing the Medical sector's gain of 6.34% and the S&P 500's gain of 2.08%.
The upcoming earnings release of Merck will be of great interest to investors. On that day, Merck is projected to report earnings of $2.27 per share, which would represent a year-over-year decline of 12.02%. In the meantime, our current consensus estimate forecasts the revenue to be $17.61 billion, indicating a 1.94% growth compared to the corresponding quarter of the prior year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $2.97 per share and a revenue of $67.25 billion, signifying shifts of -66.93% and +3.45%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Merck. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.33% lower. As of now, Merck holds a Zacks Rank of #3 (Hold).
In terms of valuation, Merck is presently being traded at a Forward P/E ratio of 51.22. For comparison, its industry has an average Forward P/E of 18.02, which means Merck is trading at a premium to the group.
We can additionally observe that MRK currently boasts a PEG ratio of 6.16. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.3 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 98, finds itself in the top 40% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.